Jamie Macdonald, Parexel
July 2, 2021 11:36 AM EDT
Deals
R&D

The CRO mad­ness con­tin­ues as Gold­man Sachs-backed buy­er group shells out $8.5B for Parex­el

Kyle Blankenship

The Covid-19 pan­dem­ic has kicked the con­tract re­search field in­to high gear, with a par­tic­u­lar fo­cus on de­cen­tral­ized tri­als as the re­search tool of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Trump blog: Judge ex­tends na­tion­wide block on NIH pay­ment cuts

RFK Jr. read­ies re­view of child­hood vac­cine sched­ule af­ter pledg­ing not to

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times